Developer docs
API playgroundTry for free, no card

Search company profiles

Tevosol

Full company profile

uuid0003w8y

Namestring
Tevosol
Websiteurl
tevosol.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS), a platform intended to rehabilitate marginal donor organs and increase the supply of organs available for transplantation. The company positioned itself in the organ-preservation/transplantation medicine segment, with leadership pairing executive function (CEO Ron Mills) alongside clinical investigation depth (Vice President & Director of Clinical Investigation Jayan Nagendran). Tevosol operated with a small team of 1-10 employees and secured approximately $4.55M across three early-stage funding rounds in 2016 (with VA Angels participation), 2017 and 2019 from undisclosed investor bases.

The underlying business model relied on eventual commercialization of a regulated medical device to transplant centers and hospitals — a regulatory-intensive sales path with long development timelines and concentrated institutional buyers. No pricing, customer, distribution channel, partnership, certification, patent, or revenue data is disclosed in the available inputs. As of the supplied data, the company's tevosol.com web presence has been replaced by a HugeDomains domain-sale listing (priced at $5,695) and third-party data reports an operating status of 'closed,' indicating that the firm is not currently demonstrating active operations, customer engagement, or pipeline progression. The available evidence is insufficient to confirm continued independent operation or commercialization activity.

Short descriptiontext

Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS) to rehabilitate and expand the supply of transplantable donor organs for transplantation medicine.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ex-vivo organ support, organ preservation systems, transplant medical devices, organ transplant technology, medical device innovation
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Blood and Organ Banks621991
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Organ Transplantation Medical Devices
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tevosol has developed the Ex-Vivo Organ Support System, a medical device platform designed to preserve and support organs outside the body in order to increase the number of available organs for transplantation. The system is targeted at transplant programs and clinical investigators working to expand the supply of viable donor organs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tevosol operates as a domain name listed for sale on HugeDomains.com. The single product offering is the domain name TeVosOl.com, a 7-character .com domain available for immediate purchase or via a 24-month payment plan at 0% interest. No other products, services, or company information is available for Tevosol in the source data.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OrganOx commercializes the metra normothermic liver perfusion device, a direct ex-vivo organ support system competing for the same transplant-center customers and clinical workflow as EVOSS.

2TransMedics
TypeDirect peer
Description

TransMedics develops the Organ Care System (OCS), the most advanced commercial ex-vivo organ preservation and assessment platform for lung, heart, and liver — the same clinical use case Tevosol's EVOSS targets.

3Institut Georges Lopez (IGL)
TypeRegional player
Description

IGL manufactures static cold preservation solutions widely used in European transplant centers, serving the same preservation workflow as Tevosol's device and representing a regional competitor in the same category.

TypeBroad incumbent
Description

Thermo Fisher supplies transplant diagnostics, cell-therapy manufacturing, and laboratory reagents that support transplant workflows — a broad incumbent with tangential overlap to Tevosol's transplant-focused device mission.

TypeDirect peer
Description

XVIVO Perfusion offers machine perfusion and preservation solutions for lungs, kidneys, and hearts, making it a direct competitor in the ex-vivo organ support category where Tevosol operates.

TypeDirect peer
Description

Organ Recovery Systems' LifePort platform is a kidney perfusion device widely adopted by transplant centers — a direct functional peer to Tevosol's EVOSS in ex-vivo organ support.

TypeDirect peer
Description

Paragonix develops advanced organ preservation and transport devices (e.g., LUNGguard, BAROguard), overlapping with Tevosol's mission of expanding usable donor organs through better preservation technology.

TypeDirect peer
Description

Organ Assist develops and supplies machine perfusion devices for kidneys, livers, and lungs, and is a direct competitor in the ex-vivo organ preservation space where Tevosol competes.

TypeEmerging player
Description

Bridge to Life supplies organ preservation solutions and is expanding into device-based preservation, intersecting with Tevosol's ex-vivo organ support mission.

10Preservation Solutions
TypeEmerging player
Description

Preservation Solutions develops organ and tissue preservation chemistries used in transplant workflows, a partial-overlap emerging player in the broader organ preservation ecosystem.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tevosol

Organ Transplantation Medical Devicestevosol.com

Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS) to rehabilitate and expand the supply of transplantable donor organs for transplantation medicine.

What Tevosol does

Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS), a platform intended to rehabilitate marginal donor organs and increase the supply of organs available for transplantation. The company positioned itself in the organ-preservation/transplantation medicine segment, with leadership pairing executive function (CEO Ron Mills) alongside clinical investigation depth (Vice President & Director of Clinical Investigation Jayan Nagendran). Tevosol operated with a small team of 1-10 employees and secured approximately $4.55M across three early-stage funding rounds in 2016 (with VA Angels participation), 2017 and 2019 from undisclosed investor bases.

The underlying business model relied on eventual commercialization of a regulated medical device to transplant centers and hospitals — a regulatory-intensive sales path with long development timelines and concentrated institutional buyers. No pricing, customer, distribution channel, partnership, certification, patent, or revenue data is disclosed in the available inputs. As of the supplied data, the company's tevosol.com web presence has been replaced by a HugeDomains domain-sale listing (priced at $5,695) and third-party data reports an operating status of 'closed,' indicating that the firm is not currently demonstrating active operations, customer engagement, or pipeline progression. The available evidence is insufficient to confirm continued independent operation or commercialization activity.

Tevosol firmographics

Firmographics
Name
Tevosol
Website
https://tevosol.com
Company type
Private
Founded year
2015
Operating status
Closed
Headcount range
1–10 employees
Short description
Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS) to rehabilitate and expand the supply of transplantable donor organs for transplantation medicine.
Ownership category
akta.pro rank

Tevosol industry classification

Industry
Product category
Organ Transplantation Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Blood and Organ Banks (621991)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Ex-vivo organ support
  • Organ preservation systems
  • Transplant medical devices
  • Organ transplant technology
  • Medical device innovation

Where Tevosol is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Markets served

Tevosol business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Tevosol product offering

Product offering

Core offering

Tevosol has developed the Ex-Vivo Organ Support System, a medical device platform designed to preserve and support organs outside the body in order to increase the number of available organs for transplantation. The system is targeted at transplant programs and clinical investigators working to expand the supply of viable donor organs.

Product overview

Tevosol operates as a domain name listed for sale on HugeDomains.com. The single product offering is the domain name TeVosOl.com, a 7-character .com domain available for immediate purchase or via a 24-month payment plan at 0% interest. No other products, services, or company information is available for Tevosol in the source data.

Differentiator

Problem solved

Functional benefit

Companies that use Tevosol

Customer profile

Ideal customer profiles1 record

Tevosol technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tevosol partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

Tevosol competitors and assessment

Company assessment

Direct peers

  • OrganOx: OrganOx commercializes the metra normothermic liver perfusion device, a direct ex-vivo organ support system competing for the same transplant-center customers and clinical workflow as EVOSS.
  • TransMedics: TransMedics develops the Organ Care System (OCS), the most advanced commercial ex-vivo organ preservation and assessment platform for lung, heart, and liver — the same clinical use case Tevosol's EVOSS targets.
  • XVIVO Perfusion: XVIVO Perfusion offers machine perfusion and preservation solutions for lungs, kidneys, and hearts, making it a direct competitor in the ex-vivo organ support category where Tevosol operates.
  • Organ Recovery Systems: Organ Recovery Systems' LifePort platform is a kidney perfusion device widely adopted by transplant centers — a direct functional peer to Tevosol's EVOSS in ex-vivo organ support.
  • Paragonix Technologies: Paragonix develops advanced organ preservation and transport devices (e.g., LUNGguard, BAROguard), overlapping with Tevosol's mission of expanding usable donor organs through better preservation technology.
  • Organ Assist: Organ Assist develops and supplies machine perfusion devices for kidneys, livers, and lungs, and is a direct competitor in the ex-vivo organ preservation space where Tevosol competes.

Regional players

  • Institut Georges Lopez (IGL): IGL manufactures static cold preservation solutions widely used in European transplant centers, serving the same preservation workflow as Tevosol's device and representing a regional competitor in the same category.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher supplies transplant diagnostics, cell-therapy manufacturing, and laboratory reagents that support transplant workflows — a broad incumbent with tangential overlap to Tevosol's transplant-focused device mission.

Emerging players

  • Bridge to Life: Bridge to Life supplies organ preservation solutions and is expanding into device-based preservation, intersecting with Tevosol's ex-vivo organ support mission.
  • Preservation Solutions: Preservation Solutions develops organ and tissue preservation chemistries used in transplant workflows, a partial-overlap emerging player in the broader organ preservation ecosystem.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Tevosol social profiles

Digital presence

Tevosol financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tevosol leadership team

Management profile

Number of profiles

Profiles2 records

Tevosol funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tevosol M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tevosol

What does Tevosol do?

Tevosol has developed the Ex-Vivo Organ Support System, a medical device platform designed to preserve and support organs outside the body in order to increase the number of available organs for transplantation. The system is targeted at transplant programs and clinical investigators working to expand the supply of viable donor organs.

Is Tevosol a public or private company?

Tevosol is a private company. It is classified as venture growth investor backed and is currently closed.

When was Tevosol founded?

Tevosol was founded in 2015. It employs 1 to 10 people.

Where is Tevosol based?

Tevosol is headquartered in Edmonton, Canada, in the North America region.

Who are Tevosol's main competitors?

Direct peers on record are OrganOx, TransMedics, XVIVO Perfusion, Organ Recovery Systems, Paragonix Technologies and Organ Assist. Institut Georges Lopez (IGL) is listed as a regional player. Thermo Fisher Scientific is listed as a broad incumbent. Emerging players are Bridge to Life and Preservation Solutions.

Does Tevosol have an API?

No public API is recorded for Tevosol.

What industry is Tevosol in?

Tevosol's product category is Organ Transplantation Medical Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GoogleU of A spinoff company merges with U.S. firm to commercialize breakthrough organ transplant technologyUniversity of Alberta spinoff Tevosol merged with U.S. firm Bridge to Life, with Bridge to Life committing $10 million to a multi-centre clinical trial and $10 million more for a heart preservation device. The partnership aims to increase lung transplant utilization from under 25% to 50%, potentially doubling annual transplants to 8,000 within two to three years.University of AlbertaU of A spinoff company merges with U.S. firm to commercialize breakthrough organ transplant technologyUniversity of Alberta spinoff Tevosol merged with U.S. firm Bridge to Life, with Bridge to Life committing $10 million to a multi-centre clinical trial and $10 million more for a heart preservation device. The lung device aims to double transplant utilization from under 25% to 50%, potentially enabling 8,000 transplants annually within two to three years.PR NewswireBridge to Life and Tevosol Merge to Commercialize Portable Normothermic Machine Preservation Technology Platform for Organ TransplantationBridge to Life, Ltd., a leading global supplier of organ preservation solutions, has merged with Tevosol, Inc., a clinical stage medical device startup, to develop and commercialize portable ex-vivo lung perfusion (EVLP) technology for organ transplantation. Bridge to Life has made a significant financial commitment to manufacture, trial, and launch Tevosol's EVOSS platform, with the stated goal of increasing donor lung availability for the nearly 1,000 candidates on the US lung transplant waiting list. EVOSS Lung pivotal clinical trials are scheduled to begin in 2021, while product development and manufacturing will remain in Edmonton, Canada.PR NewswireTevosol Closes $2M Seed RoundTevosol, Inc. has closed a $2 million CAD seed financing round to support the completion of human trials for its portable perfusion machine and accelerate commercial development. The company plans to conclude prototype trials at the University of Alberta within a month and initiate FDA pivotal clinical trials within a year.FinSMEsMedical Device Company Tevosol Secures $2M in FundingTevosol, an Edmonton-based medical device company, secured $2M in undisclosed funding. The company will use the funds to develop its organ preservation device prototype for clinical use and begin a lung transplant trial at the University of Alberta. The device keeps hearts, lungs, livers, and kidneys viable longer.